Dear Recovery Colleagues,
In view of the ongoing and ever-changing public health crisis due to the coronavirus outbreak, the Recovery Conference Co-Chairs and Board of Directors have made the difficult decision to postpone further Recovery of Biological Products XIX (RXIX) in Rome, Italy to 2022. By moving to 2022, we hope it will alleviate any health concerns, as well as avoid travel restrictions that may limit the ability to travel to the conference.
Given the postponement of the conference, we will be re-opening the call for abstracts in the Fall of 2021 and repeating the abstract selection process afresh. To be considered for the rescheduled conference dates in 2022, submitters will have the opportunity to either submit completely new abstracts or to update and resubmit their original abstracts.
We are sincerely grateful for the time, dedication and patience of the Recovery Board of Directors, Sponsors, Session Chairs, and Abstract Submitters who make this conference possible. It is our intention to deliver an incredible conference in 2022.
The outbreak has focused the world’s attention on the tremendous contributions that we can make in this sector as well as the urgency for more rapid development of biologics with appropriate regulatory flexibility to facilitate moving at pandemic speed. With this in mind, we are convinced that getting together is more important than ever and so we look forward to your presence at this exciting conference in 2022.
In the meantime, we are excited to announce that Recovery will be running virtual Satellite Meetings designed to maintain the involvement and momentum of the Recovery community. Please look out for more detailed announcements and updates via the Recovery website and email. We look forward to connecting throughout the upcoming year!
The RXIX Co-Chairs
Suzy Farid (UCL, UK), Nihal Tugcu (Sanofi, USA), Arne Staby (Novo Nordisk, Denmark)